Batanopride

Batanopride (BMY-25,801) is an antiemetic drug of the benzamide class which acts as a selective 5-HT₃ receptor antagonist.[1] It was trialled to reduce nausea during cancer chemotherapy, but was never approved for medical use due to dose-limiting side effects including hypotension and long QT syndrome.[2]

Batanopride

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-(3-oxobutan-2-yloxy)benzamide
CAS Number	102670-46-2^N
PubChem CID	59692
ChemSpider	53849^Y
UNII	1AT99K728N
ChEMBL	ChEMBL38594^Y
Chemical and physical data
Formula	C17H26ClN3O3
Molar mass	355.86 g·mol^−1
3D model (JSmol)	Interactive image
SMILES Clc1cc(c(OC(C(=O)C)C)cc1N)C(=O)NCCN(CC)CC
InChI InChI=1S/C17H26ClN3O3/c1-5-21(6-2)8-7-20-17(23)13-9-14(18)15(19)10-16(13)24-12(4)11(3)22/h9-10,12H,5-8,19H2,1-4H3,(H,20,23)^Y Key:ZYOJXUNLLOBURP-UHFFFAOYSA-N^Y
^NY (what is this?)  (verify)

References

1. Gylys JA, Wright RN, Nicolosi WD, Buyniski JP, Crenshaw RR (March 1988). "BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties". The Journal of Pharmacology and Experimental Therapeutics. 244 (3): 830–7. PMID 2978041.
2. Fleming GF, Vokes EE, McEvilly JM, Janisch L, Francher D, Smaldone L. "Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis". Cancer Chemotherapy and Pharmacology. 28 (3): 226–7. doi:10.1007/bf00685516. PMID 1855280.